Abstract
Randomized, double-blind, focused on transitions-label comparative efficacy and safety of oral rivaroxaban to placebo for reducing the risk of death, myocardial infarction or stroke in patients with chronic heart failure and major coronary heart disease after hospitalization for exacerbation of heart failure